Earnings ·
Summit Therapeutics reported Q2 2026 financial results, ending the period with $690.7 million in cash and investments
SMMTSummit Therapeutics Inc.
Summit Therapeutics reported Q2 2026 financial results, ending the period with $690.7 million in cash and investments. The company reported a GAAP net loss of $215.7 million ($0.28 per share) and a non-GAAP net loss of $147.0 million ($0.19 per share). Key operational updates include the FDA's acceptance of a BLA for ivonescimab in EGFR-mutated NSCLC with a PDUFA date of November 14, 2026. Updated HARMONi study analysis showed a consistent overall survival hazard ratio of 0.76 across Asian and western patient subgroups. Additionally, Summit sold its Phase III antibiotic asset, ridinilazole, to Biossil, Inc. for $500,000 upfront and up to $104.5 million in milestones. The company is a biopharmaceutical oncology company focused on the development and commercialization of medicinal therapies for cancer.